The impact of COVID-19 on clinical course and treatment among patients with juvenile systemic sclerosis
Amra Adrovic1, Mehmet Yıldız2, Fatih Haşlak2, Sezgin Şahin2, Oya Köker3, Aybüke Günalp2, Kenan Barut2, Özgür Kasapçopur2
1Pediatric Rheumatology, Koç University Hospital, Istanbul, Türkiye
2Pediatric Rheumatology, Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Istanbul, Türkiye
3Pediatric Rheumatology, Marmara University Faculty of Medicine, Istanbul, Türkiye
Keywords: Coronavirus disease 2019, interstitial lung disease, juvenile systemic sclerosis, SARS-CoV-2, tocilizumab.
Objectives: This study aimed to explore the influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic among patients with juvenile systemic sclerosis (JSS).
Patients and methods: Twenty-seven patients (22 females, 5 males; mean age: 20 years; range, 17 to 22 years) diagnosed with JSS and followed up at the department of pediatric rheumatology were included in the cross-sectional study. A web-based survey was performed by focusing on patients’ complaints, accessibility to health care, and compliance with routine treatment from January 1, 2021, to January 10, 2021.
Results: Five (18.5%) patients had deterioration of the disease, while six (22.2%) patients reported irregular usage of their routine scleroderma treatment during the last six months. Nine (33.3%) patients had missed their routine clinic control since the proclamation of the SARS-CoV-2 pandemic. Seven (25.9%) patients had household contact with coronavirus disease 2019 (COVID-19). Four (14.8%) patients were diagnosed with COVID-19, and only one (3.7%) was hospitalized. Nine patients were under biological treatment (tocilizumab); however, only one of them was diagnosed with COVID-19.
Conclusion: The COVID-19 pandemic has not significantly disrupted the medical care of JSS patients. Telemedicine could be an acceptable option for JSS patients disenabled to come to the hospital.
Citation: Adrovic A, Yıldız M, Haşlak F, Şahin S, Köker O, Günalp A, et al. The impact of COVID-19 on clinical course and treatment among patients with juvenile systemic sclerosis. Arch Rheumatol 2023;38(x):i-vii.